QPPV.COM KNOWLEDGE ASSESSMENT

Belantamab Mafodotin: Mechanism, Clinical Safety and Pharmacovigilance — Knowledge Assessment

Test your understanding of the concepts covered by Belantamab mafodotin: Mechanism, Clinical Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Why should case review not rely only on a patient's report of eye symptoms when evaluating possible corneal toxicity?

Corneal examination findings may occur without corresponding symptoms or visual-acuity change Patient-reported symptoms are never relevant to ocular safety assessment All corneal findings necessarily cause permanent vision loss Symptoms identify the affected eye more reliably than an ophthalmic examination

Question 2 of 10 Which patient and treatment context matches the current EU indication described in the article?

Adults with newly diagnosed multiple myeloma receiving belantamab mafodotin alone Adults with relapsed or refractory multiple myeloma receiving belantamab mafodotin with either BVd or BPd under the applicable prior-therapy criteria Adults with relapsed or refractory multiple myeloma receiving belantamab mafodotin with any partner medicines selected without regard to prior therapy Adults with relapsed or refractory multiple myeloma receiving belantamab mafodotin only after at least three previous therapies

Question 3 of 10 How should a historical case from the earlier EU monotherapy authorisation be used in a current aggregate safety review?

Pool it directly with current combination cases because the active substance is unchanged Exclude it from all safety review because the earlier authorisation ended Retain it as potentially informative, while accounting for its distinct indication, regimen, population and authorisation period Reclassify it as a current BVd case if the patient received a proteasome inhibitor at any point

Question 4 of 10 A corneal ulcer is identified during treatment. Which management-related information is especially important to capture in the safety record?

Whether treatment was interrupted and the clinical status of healing before any resumption Only whether the patient described pain at the time of the next infusion Whether the patient had used any eye drops, without recording the ulcer or dose decision Only the regimen name, because the product information provides a standard response

Question 5 of 10 Which statement correctly distinguishes seriousness from expectedness in case processing?

A known event cannot be serious or reportable Seriousness and expectedness are separate assessments; a known event may still be serious An event is unexpected whenever it results in hospitalization Expectedness determines whether an event meets regulatory seriousness criteria

Question 6 of 10 A patient receiving combination therapy develops fever and an infection. Which information best supports meaningful safety assessment?

The infection term and the date of the next planned cycle Infection site and organism where known, investigations, neutrophil count, treatment, outcome and timing of regimen components The belantamab dose alone, because infection is unrelated to background disease A conclusion that the infection was caused by the most recently administered medicine

Question 7 of 10 Which statement best describes the QPPV's role in the safety system described in the article?

The QPPV makes individual treatment decisions and replaces the treating physician The QPPV supports oversight of the MAH pharmacovigilance system and has access to relevant safety information The QPPV personally performs every ophthalmic examination before dosing The QPPV determines clinical causality for every report without input from other functions

Question 8 of 10 A reviewer proposes that the ADC mechanism proves a reported adverse event was caused by belantamab mafodotin. What is the most appropriate pharmacovigilance interpretation?

A plausible mechanism establishes causality whenever the event follows an infusion Mechanistic plausibility can inform assessment but does not establish causality in an individual case Mechanistic plausibility is irrelevant and should never be considered The antibody component establishes causality, but the payload component does not

Question 9 of 10 Which information is most useful when assessing thrombocytopenia in a patient receiving a belantamab combination?

The platelet trend, bleeding manifestations, transfusions, anticoagulant exposure and relevant disease or treatment context The platelet value at the time of the report only The product dose alone, because partner medicines do not affect interpretation The event term and seriousness classification, without laboratory or clinical detail

Question 10 of 10 Which dosing schedule correctly distinguishes the two current EU combination regimens?

BVd starts at 2.5 mg/kg every three weeks; BPd uses 2.5 mg/kg once in cycle 1, then 1.9 mg/kg every four weeks from cycle 2 BVd uses 1.9 mg/kg every four weeks; BPd starts at 2.5 mg/kg every three weeks throughout treatment Both regimens use 2.5 mg/kg every four weeks from cycle 1 Both regimens use 1.9 mg/kg every three weeks from cycle 1

Belantamab Mafodotin: Mechanism, Clinical Safety and Pharmacovigilance — Knowledge Assessment

Cookie Settings